Wayne B Batchelor, Thaddeus R Tolleson, Yao Huang, Rhonda L Larsen, R Michael Mantell, Patricia Dillard, Marie Davidian, Daowen Zhang, Warren J Cantor, Michael H Sketch, E Magnus Ohman, James P Zidar, Daniel Gretler, Peter M DiBattiste, James E Tcheng, Robert M Califf, Robert A Harrington
BACKGROUND: The relative anti-aggregatory effects of currently prescribed platelet glycoprotein IIb/IIIa receptor antagonists during and after percutaneous coronary intervention for acute coronary syndromes have not been established. METHODS AND RESULTS: We randomized 70 acute coronary syndrome patients undergoing percutaneous coronary intervention to receive abciximab, eptifibatide, or tirofiban at doses used in the Evaluation of Platelet IIb/IIIa Inhibitor for STENTing (EPISTENT), Platelet glycoprotein IIb/IIIa in Unstable angina Receptor Suppression Using Integrilin Therapy (PURSUIT), and Platelet Receptor Inhibition in ischemic Syndrome Management in Patients Limited by Unstable Signs and symptoms (PRISM-PLUS)/Randomized Efficacy Study of Tirofiban for Outcomes and Restenosis (RESTORE) trials, respectively...
September 17, 2002: Circulation